Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +37.44%
#3 Glidr Glidr +35.94%
#4 Humanity Humanity +25.03%
#5 Tutorial Tutorial +21.66%
#6 Enso Enso +21.56%
#7 Codatta Codatta +19.97%
#8 Walrus Walrus +19.47%
#9 BOOK OF MEME BOOK OF MEME +18.59%
#10 Ribbita by Virtuals Ribbita by Virtuals +13.44%
Coin of the day
EXOD EXOD
Innstillinger
Språk
NORSK
Valuta
USD
Tema
DermTech, Inc. DermTech, Inc.

DermTech, Inc.

DMTK
Rangering i aksjer #37065
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla,... DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis. This assay plays a crucial role in enhancing the early identification of genomic abnormalities, effectively aiding in the exclusion of melanoma and often removing the need for invasive surgical biopsies of suspicious pigmented lesions. The company further provides specialized adhesive kits for convenient skin sample collection. Additionally, they offer gene expression assays designed to analyze key inflammatory pathways such, as Th1, Th2, IFN-gamma, and Th17. Looking ahead, DermTech is actively developing a pipeline of new products, which includes DNA risk assessment tools for UV damage, diagnostic tests for non-melanoma skin cancers, and rule-out tests for cutaneous T-cell lymphoma. They also extend their services by delivering health-related information and support through digital and telecommunication platforms. DermTech's diagnostic products and services are primarily targeted towards medical professionals in the fields of pathology and oncology.
Aksjekurs
$0.069
Sist synkronisert: 2024-07-22
Markedsverdi
$2.06M
Endring (1 dag)
-1.43%
Endring (1 år)
0.00%
Land
US
Handel DermTech, Inc. (DMTK)

Kategori

Healthcare
P/E-forhold for DermTech, Inc. (DMTK)
P/E-forhold per August 2026 TTM: -0.03
Ifølge DermTech, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -0.03. Ved slutten av 2022 hadde selskapet en P/E på -0.46.
P/E-forholdshistorikk for DermTech, Inc. fra 2016 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) -0.03 -94.37%
2023 -0.54 17.86%
2022 -0.46 -92.18%
2021 -5.83 -61.42%
2020 -15.10 249.93%
2019 -4.32 -102.06%
2018 209.29 -100.01%
2017 -3.00M 4,455.00%
2016 -65.77K 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 31.59 -104,029.28%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 35.83 -117,968.09%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 -227.89 749,537.17%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 38.69 -127,373.03%
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.